Lung Cancer Clinical Trial
Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)
Summary
Tomivosertib combined with pembrolizumab in Subjects with PD-L1 positive NSCLC
Full Description
A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy
Eligibility Criteria
Inclusion Criteria:
Inclusion Criteria for Cohort A: Subjects who meet all of the following criteria will be eligible to participate in Cohort A of the study:
1. Have initiated first-line therapy for NSCLC with pembrolizumab and satisfy the following:
Have tumor PD-L1 ≥1% by 22C3 IHC;
Are judged by the Principal Investigator as tolerating pembrolizumab monotherapy; and
Have been on pembrolizumab for at least 3 months (measured from actual first dose date to first dose date of the current study) and the most recent scans are the first scans to objectively demonstrate Progressive Disease per RECIST 1.1
The first scan conducted a minimum of 21 days after first dose of anti-PD-(L)1 therapy must have shown either SD, PR, or CR (ie, not Progressive Disease) per RECIST 1.1; and
The 2 most recent scans (including 1 demonstrating Progressive Disease) are available to be reviewed
Inclusion Criterion for Cohort B
Subjects who meet the following criterion will be eligible to participate in Cohort B of the study:
1. Are eligible for single-agent pembrolizumab for advanced/metastatic NSCLC in accordance with the package insert and have tumor PD-L1 ≥50% by 22C3 IHC
• Must not have been treated previously with platinum-based chemotherapy in the advanced/metastatic setting. Note: Subjects may have received chemotherapy and/or anti PD (L)1 therapy in the neo/adjuvant setting, provided the last dose of therapy was >9 months prior to randomization.
Subjects who meet the following criterion will be eligible to participate in Cohort C of the study:
1. Have initiated IL therapy for NSCLC and completed all planned (eg, 4 to 6 cycles) platinum-based chemotherapy with at least 2 cycles in combination with pembrolizumab; must not have had progressive disease on tumor staging imaging scans following completion of all planned platinum chemotherapy
Are eligible for maintenance therapy with pembrolizumab ± pemetrexed in accordance with the package insert
Have tumor PD-L1 ≥1%
The last dose of platinum-based chemotherapy must be within 8 weeks of the first dose of the study drug in this study
Inclusion Criterion for All Cohorts
Subjects must also meet all of the following criteria to be eligible to participate in the study:
Have histologically confirmed NSCLC that is inoperable, locally advanced or metastatic (Stage IIIb/IV)
Have available at the site a representative formalin-fixed, paraffin-embedded tumor specimen that enabled diagnosis of NSCLC in a tissue block (preferred) or 10 unstained, serial slides, accompanied by an associated pathology report. Note: If the archival tissue is neither sufficient nor available, the subject may still be eligible, upon discussion with the Medical Monitor
Have provided written informed consent and any authorizations required by local law
Are ≥18 years of age
Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Exclusion Criteria:
Have NSCLC with epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations
Have gastrointestinal (GI) disease (eg, gastric or intestinal bypass surgery, pancreatic enzyme insufficiency, malabsorption syndrome, symptomatic inflammatory bowel disease, chronic diarrheal illness, and/or bowel obstruction) that may interfere with drug absorption or with interpretation of GI AEs
Have known symptomatic brain metastases requiring >10 mg/day of prednisone (or its equivalent). Subjects with previously diagnosed brain metastases are eligible if they have completed their treatment, have recovered from the acute effects of radiation therapy or surgery prior to randomization, fulfill the steroid requirement for these metastases, the 2 most recent serial magnetic resonance imaging (MRI) scans conducted >28 days apart show no central nervous system progression, and are neurologically stable and asymptomatic
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 58 Locations for this study
Mobile Alabama, 36526, United States More Info
Principal Investigator
Tucson Arizona, 85711, United States More Info
Principal Investigator
Alhambra California, 91801, United States More Info
Principal Investigator
Los Angeles California, 90025, United States More Info
Principal Investigator
Los Angeles California, 90033, United States More Info
Principal Investigator
Merced California, 95340, United States More Info
Principal Investigator
Newport Beach California, 92663, United States More Info
Principal Investigator
Orange California, 92868, United States More Info
Principal Investigator
Porter Ranch California, 91326, United States More Info
Principal Investigator
San Francisco California, 94117, United States More Info
Principal Investigator
San Luis Obispo California, 93401, United States More Info
Principal Investigator
San Luis Obispo California, 93401, United States More Info
Principal Investigator
Santa Ana California, 92705, United States More Info
Principal Investigator
Santa Maria California, 93454, United States More Info
Principal Investigator
Stockton California, 95204, United States More Info
Principal Investigator
Colorado Springs Colorado, 80907, United States More Info
Principal Investigator
Brooksville Florida, 34613, United States More Info
Principal Investigator
Hollywood Florida, 33021, United States More Info
Principal Investigator
Palm Bay Florida, 32901, United States More Info
Principal Investigator
Pembroke Pines Florida, 33028, United States More Info
Principal Investigator
Pensacola Florida, 32503, United States More Info
Principal Investigator
Columbus Georgia, 31904, United States More Info
Principal Investigator
Lexington Kentucky, 40503, United States More Info
Principal Investigator
Louisville Kentucky, 40207, United States More Info
Principal Investigator
Annapolis Maryland, 21401, United States More Info
Principal Investigator
Columbia Maryland, 21044, United States More Info
Principal Investigator
Boston Massachusetts, 02111, United States More Info
Principal Investigator
Detroit Michigan, 48202, United States More Info
Principal Investigator
Saint Louis Park Minnesota, 55416, United States More Info
Principal Investigator
Billings Montana, 59102, United States More Info
Principal Investigator
New York New York, 10032, United States More Info
Principal Investigator
Asheville North Carolina, 28806, United States More Info
Principal Investigator
Canton Ohio, 44708, United States More Info
Principal Investigator
Dover Ohio, 44622, United States More Info
Principal Investigator
Kettering Ohio, 45429, United States More Info
Principal Investigator
Massillon Ohio, 44646, United States More Info
Principal Investigator
Toledo Ohio, 43614, United States More Info
Principal Investigator
Eugene Oregon, 97401, United States More Info
Principal Investigator
Portland Oregon, 97213, United States More Info
Principal Investigator
Greenville South Carolina, 29615, United States More Info
Principal Investigator
Watertown South Dakota, 57201, United States More Info
Principal Investigator
Austin Texas, 78745, United States More Info
Principal Investigator
Beaumont Texas, 77701, United States More Info
Principal Investigator
Bedford Texas, 76022, United States More Info
Principal Investigator
Dallas Texas, 75231, United States More Info
Principal Investigator
Dallas Texas, 75246, United States More Info
Principal Investigator
Denton Texas, 76201, United States More Info
Principal Investigator
El Paso Texas, 79902, United States More Info
Principal Investigator
Flower Mound Texas, 75028, United States More Info
Principal Investigator
Fort Worth Texas, 76104, United States More Info
Principal Investigator
Houston Texas, 77030, United States More Info
Principal Investigator
Paris Texas, 75460, United States More Info
Principal Investigator
Plano Texas, 75075, United States More Info
Principal Investigator
Tyler Texas, 75702, United States More Info
Principal Investigator
Webster Texas, 77598, United States More Info
Principal Investigator
Fairfax Virginia, 22031, United States More Info
Principal Investigator
Everett Washington, 98201, United States More Info
Principal Investigator
Spokane Washington, 99204, United States More Info
Principal Investigator
Morgantown West Virginia, 26506, United States More Info
Principal Investigator
How clear is this clinincal trial information?